TP53 and non-small cell lung carcinoma: Intratumoral injection of Ad-p53 in NSCLC patients resulted in a clinical response in 72% of patients [116], and intratumoral injection into patients with head and neck cancer resulted in a clinical response in 47% of patients (Table 1) [117].